Xeris Biopharma Holdings, Inc. is listed among the 10 Best Biotech Stocks to Buy Under $10, focusing on therapies for chronic endocrine and neurological diseases. Key products include Recorlev, Gvoke, and Keveyis, with a promising pipeline candidate, XP-8121, in Phase 3 for hypothyroidism.

Xeris Biopharma Holdings, Inc. reported a record Q2 2025 revenue of $71.5 million, a 49% year-over-year increase, with Recorlev sales surging 136%. The company raised its 2025 revenue guidance to $280–$290 million, presenting a long-term growth vision targeting $750 million total revenue by 2030.

Xeris Biopharma Holdings, Inc. positions itself as a competitive player in the biotech sector with potential in endocrine disease treatment. While Recorlev drives immediate revenue growth, XP-8121 offers diversification and long-term revenue expansion, signaling confidence in sustaining growth through existing therapies and future product launches.

Read more at Yahoo Finance: Xeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 Revenue